Figure 2 | Scientific Reports

Figure 2

From: Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen

Figure 2

Combining Tamoxifen with (A) Alpelisib or (B) Buparlisib Attenuates Signal Transduction Downstream of PI3K in ZR75-1 Cells (tamoxifen: 8 µM; alpelisib: 5 µM; and buparlisib: 5 µM). Cells treated with a combination of tamoxifen with alpelisib or buparlisib had lower pAKT, pGSK3β, p-p70S6K, and p4EBP1 expression levels at 3, 8, and 24 hours after treatment, compared with tamoxifen-treated or control cells.

Back to article page